Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000439314 | SCV000535804 | uncertain significance | not provided | 2017-01-06 | criteria provided, single submitter | clinical testing | A variant of uncertain significance has been identified in the ALMS1 gene. The T2339K variant has not been published as a pathogenic variant or been reported as a benign variant to our knowledge. This variant was not observed with any significant frequency in both the Exome Aggregation Consortium and in approximately 6,00 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, indicating it is not a common benign variant in these populations. The T2339K variant is a semi-conservative amino acid substitution, which may impact secondary protein structure as these residues differ in some properties. This substitution occurs at a position that is conserved in mammals. Furthermore, in silico analysis predicts this variant is probably damaging to the protein structure/function.Therefore, based on the currently available information, it is unclear whether this variant is pathogenic or benign. This result cannot be interpreted for diagnosis or used for family member screening at this time. As Alstrom syndrome due to pathogenic variants in the ALMS1 gene is an autosomal recessive disease, it is expected that an affected individual would harbor variants in both alleles of the ALMS1 gene (in trans). No second variant was identified by this sequencing or deletion/duplication analysis. The possibility that this patient harbors a second ALMS1 variant that is undetectable by this test cannot be excluded. |
Counsyl | RCV000667850 | SCV000792360 | uncertain significance | Alstrom syndrome | 2017-06-14 | criteria provided, single submitter | clinical testing | |
Natera, |
RCV000667850 | SCV002082851 | uncertain significance | Alstrom syndrome | 2021-09-09 | no assertion criteria provided | clinical testing |